BlossomHill Therapeutics IPO
BlossomHill Therapeutics is a biopharmaceutical company focused on developing novel therapeutic candidates. The company operates in the competitive biotech space, though specific details about its drug pipeline and therapeutic areas have not been publicly disclosed. Investor interest would depend on clinical trial results and regulatory milestones.
Key Facts
| Industry | Biotechnology |
| Funding | $125 million raised through IPO (August 2026) |
About BlossomHill Therapeutics
BlossomHill Therapeutics operates in the biopharmaceutical sector, working to develop therapeutic solutions. The company's specific focus areas, drug candidates, and stage of clinical development have not been widely publicized.
Without detailed public information about the company's pipeline, partnerships, or clinical trial progress, it's difficult to assess BlossomHill's competitive positioning within the broader biotech landscape. The company would need to provide substantial disclosure about its programs and development strategy as part of any IPO process.
IPO Status
BlossomHill Therapeutics has completed its initial public offering on the Nasdaq under the ticker symbol BLSM. The company priced its IPO at $125 million in early August 2026, with shares priced at up to $17 per share. The IPO proceeds will fund the development of BH-30643, the company's EGFR inhibitor candidate being developed as a challenger to AstraZeneca's Tagrisso for lung cancer treatment. The biotech is backed by Janus Henderson and is currently advancing BH-30643 through Phase 1/2 clinical trials for lung cancer. Multiple financial news sources confirmed the IPO pricing and terms were set in early August 2026, with the company beginning trading shortly thereafter. The IPO represents one of several recent biotechnology public offerings focused on oncology therapeutics.
Competitors
Frequently Asked Questions
Does BlossomHill Therapeutics have a stock?
No, BlossomHill Therapeutics has not had an IPO yet. The company remains privately held, though reports suggest it may be considering going public. Sign up for alerts to stay informed.
When is the BlossomHill Therapeutics IPO date?
BlossomHill Therapeutics has not announced an official IPO date. No public filing has been made, and the timeline remains uncertain. Sign up for alerts to stay informed.
How can I buy BlossomHill Therapeutics stock?
BlossomHill Therapeutics stock is not currently available for purchase as the company is privately held. Once the company goes public, shares would be tradeable through standard brokerage accounts. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts